HiRO - Harvest Integrated Research Organization’s Post

The final part is here! We are sharing how to realize the value & benefits of #patientcentric trials: Integration and utilization can lead to financial impact by accelerating clinical trials getting drugs to the market faster. By embracing #patientcentric protocol design, we increase recruitment and retention by making trials more accessible and convenient for potential participants. Traditional methods of running a trials run often see 1 in 4 patients drop out because of trial length and complexity, burden and cost, and lack of support at trial site.    However, with patient-centric approaches, we can bring trials to patients in their own community either conducting visits in their home or supporting a site in their community to participate in clinical research. By investing in patient-centric solutions, our pharma partners accelerate their timelines and speed up their clinical trials.   Read more about it here https://lnkd.in/eVBizhxQ

Market Access teams need to ensure that payer insights are taken into account when the clinical program is designed. One very important aspect in this context is to ensure clarity about the differences in payer (and other stakeholder) requirements across the different key markets. This will enable the Clinical Development team to make more robust design choices and conscious trade-off decisions so that the clinical program can deliver the best possible data needed to support the chosen strategy. For more insights visit our website to read the full Re-thinking Market Access series: https://lnkd.in/drPfnHzR #MarketAccess #BusinessStrategy #Pharma #LifeScience

Market Access teams need to ensure that payer insights are taken into account when the clinical program is designed. One very important aspect in this context is to ensure clarity about the differences in payer (and other stakeholder) requirements across the different key markets. This will enable the Clinical Development team to make more robust design choices and conscious trade-off decisions so that the clinical program can deliver the best possible data needed to support the chosen strategy. For more insights visit our website to read the full Re-thinking Market Access series: https://lnkd.in/dyyB6F85 #MarketAccess #BusinessStrategy #Pharma #LifeScience

Market Access teams need to ensure that payer insights are taken into account when the clinical program is designed. One very important aspect in this context is to ensure clarity about the differences in payer (and other stakeholder) requirements across the different key markets. This will enable the Clinical Development team to make more robust design choices and conscious trade-off decisions so that the clinical program can deliver the best possible data needed to support the chosen strategy. For more insights visit our website to read the full Re-thinking Market Access series: https://lnkd.in/dyyB6F85 #MarketAccess #BusinessStrategy #Pharma #LifeScience

Market Access teams need to ensure that payer insights are taken into account when the clinical program is designed. One very important aspect in this context is to ensure clarity about the differences in payer (and other stakeholder) requirements across the different key markets. This will enable the Clinical Development team to make more robust design choices and conscious trade-off decisions so that the clinical program can deliver the best possible data needed to support the chosen strategy. For more insights visit our website to read the full Re-thinking Market Access series: https://lnkd.in/drPfnHzR #MarketAccess #BusinessStrategy #Pharma #LifeScience

What’s the secret to keeping patients engaged during a clinical trial? 📣 Transparent communication Participants want proactive outreach, access to user-friendly digital platforms, and open lines of communication from clinical research to trial completion. It’s truly that simple! As shared in a recent article from Rebecca Starkie of Advanced Clinical, the overwhelming purpose of participating in a clinical trial is to advance research and help others. Clinical trial participants have a deep desire to make a difference with innovative treatments and specialized care – and we as research organizations, pharma sponsors and healthcare professionals need to prioritize active engagement to develop meaningful treatments! Read the full article with interesting study findings here: https://bit.ly/3vrJEZK #ClinicalResearch #ClinicalTrials #Pharma

Dive into the future of clinical trials! 🚀 Experience seamless studies with our automated processes and on-demand setup. Harmony at every step. Try a FREE demo @ https://lnkd.in/eWC9d4zT #ClinicalTrials #Biopharma #CTMS #eTMF #SimpleTrials #clinicaloperations

In #RareDisease development, close alignment with #patients needs and expectations is indispensable and #PatientOrganizations are able to provide this connection. For a successful collaboration, it is essential for pharma to develop a good understanding of patient organizations and maintain a respectful approach. Read our latest white paper for more insights: https://bit.ly/3IiXJvy #RareDiseaseDay

Market Access teams need to make sure to create and disseminate cross-functional understanding of the evidence needs of payers and HTA bodies, what kind of evidence they are asking for and how they will look and interpret this data. There also needs to be a shared understanding of what the implications are if certain evidence is not available in time so that strategic trade-off decisions can be taken consciously. For further insights on achieving market access excellence through a strategic integrated evidence generation plan, click the link below. https://lnkd.in/dh8fQzcG #MarketAccess #BusinessGrowth #Pharma #LifeScience

Do you want to know more about Global Trends in phrama R&D? In IQVIA Institute's report you can find trends in new drug launches and the overall number of initiated clinical trials. It also profiles the state of R&D funding and the activity of companies of different types. The results of research are compared to the input effort in a Clinical Development Productivity Index. Let me know if you need further details.